Mottola Frank 4

What Happened Frank Mottola, SVP and Chief Technical Operations Officer at Supernus Pharmaceuticals (SUPN), had 3,750 shares result from the conversion/vesting of performance-based awards on March 6, 2026 (reported on a Form 4 filed March 10, 2026). To satisfy tax withholding, 1,793 shares were surrendered/withheld (valued at $54.73 each, ~ $98,131). Separately, 1,623 shares were sold in an open-market transaction on March 9, 2026 at $53.65 per share for proceeds of about $87,074. The underlying award had a $0 exercise price, consistent with vested performance share units rather than a cash option exercise.

Key Details

• Primary dates: conversion/vesting on 2026-03-06; open-market sale on 2026-03-09; Form 4 filed 2026-03-10. Filing appears timely.
• Vesting/conversion: 3,750 shares (coded M — exercise/conversion of derivative) acquired at $0.00.
• Tax withholding: 1,793 shares surrendered/withheld (code F) at $54.73/share, amount ≈ $98,131.
• Open-market sale: 1,623 shares (code S) at $53.65/share, proceeds ≈ $87,074.
• Shares owned after the transactions: not specified in the filing.
• Footnotes: F1 indicates shares were withheld to satisfy tax withholding on vesting; F2 notes the PSUs were awarded Feb 23, 2023 with performance objectives set June 12, 2023.
• Transaction types explained: M = conversion/exercise of a derivative (here, PSUs converting to common stock); F = shares withheld for taxes; S = sale in open market.

Context This sequence (award conversion → withholding to cover taxes → partial open-market sale) is a common, routine outcome when restricted or performance-based shares vest. The $0 exercise price and the footnotes confirm these were vested performance share units rather than a purchased option. These transactions reflect routine tax-related withholding and a personal disposition of vested shares; they are not by themselves a directional endorsement of the stock.